Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibodies - Humabs BioMed

Next Previous
Drug Profile

Research programme: monoclonal antibodies - Humabs BioMed

Alternative Names: RVC 20; RVC 58

Latest Information Update: 28 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Humabs BioMed
  • Developer Humabs BioMed; Swiss Tropical and Public Health Institute; University of California at Berkeley
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Infections

Highest Development Phases

  • No development reported Campylobacter infections; Cancer; Dengue; Ebola virus infections; Escherichia coli infections; Hepatitis B; Herpes simplex virus infections; Influenza B virus infections; Metapneumovirus infections; Middle East respiratory syndrome coronavirus; Norovirus infections; Rabies; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Staphylococcal infections; Zika virus infection

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for research development in Campylobacter-infections in Switzerland (Parenteral)
  • 28 Jun 2021 No recent reports of development identified for research development in Escherichia-coli-infections in Switzerland (Parenteral)
  • 28 Aug 2020 No recent reports of development identified for preclinical development in Zika-virus-infection in Switzerland (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top